Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19250105 | 0.81 | MAPT (0.36) | MAPTMAPK8HTTELANEADORA1 | |
| SCHEMBL2609304 | 0.80 | NNMT (0.46) | BCL2L1 | |
| SCHEMBL12903736 | 0.78 | NOS3 (0.41) | MAPTMAPK8HTTELANEADORA1 | |
| SCHEMBL19386527 | 0.77 | GPR119 (0.36) | — | |
| SCHEMBL26421186 | 0.75 | ACACB (0.40) | MAPTMAPK8HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21725532 | 0.75 | HPGD (0.37) | SMN1; SMN2 | |
| SCHEMBL16783076 | 0.74 | BTK (0.37) | MAPTMAPK8HTTADORA1SMN1; SMN2 | |
| SCHEMBL10153938 | 0.74 | MAPT (0.37) | MAPTMAPK8HTTADORA1SMN1; SMN2 | |
| SCHEMBL12113611 | 0.74 | ALDH1A1 (0.41) | MAPTMAPK8HTTADORA1SMN1; SMN2 | |
| SCHEMBL18134416 | 0.74 | ADORA1 (0.46) | MAPTADORA1SMN1; SMN2ALDH1A1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC2R, MC1R, MC3R | GPR88 169/4885MAPT 3141/4885MAPK8 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.